| Name | Title | Contact Details |
|---|
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
EV Biologics is a biotechnology company that is developing extracellular vesicles (EVs) to create diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions.
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Mitra Biotech is the global leader in therapy selection in oncology. Mitra is led by an accomplished team of diagnostic and drug development professionals and is backed by world leading venture groups with long term commitment to Mitra’s vision in personalized cancer care.